Here we used an artificial intelligence-based screening pipeline to identify molecules predicted to bind the BAZ1A bromodomain, and validated hit compounds using FSHD-specific assays in FSHD myocytes. The gene discussed is BAZ1A; the disease is facioscapulohumeral muscular dystrophy.